Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy



Status:Completed
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:19 - 80
Updated:7/28/2018
Start Date:August 2010
End Date:October 2017

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Effectiveness of a Subcutaneously Administered Long-Acting Insulin Detemir Added to Insulin Drip Therapy as Compared With Standard Insulin Drip Treatment

The investigators anticipate that the use of Detemir will decrease the duration of an insulin
drip, the dose of short-acting insulin in the drip, hospital and ICU (intensive care unit)
length of stay, improve glycemic control, and prevent rebound hyperglycemias when the insulin
drip is discontinued.


Inclusion Criteria:

- Diabetic ketoacidosis (DKA) and hyperosmolar non-ketotic states, hyperglycemia with
severe illness, pre-and postoperative states, nothing by mouth (NPO), as well as
gastric (tube feeding) and parenteral nutritional requiring insulin drip.

- Patients with type 1 and type 2 diabetes mellitus (DM) will be included.

- Patient with both types of diabetes will be among those treated with insulin drip
while being NPO, having severe concomitant illness or receiving enteral and parenteral
nutrition

- Patients will be of age 19 to 80.

Exclusion Criteria:

- Inability to consent for the study for any reason including cognitive impairment
secondary to hyperglycemia, presence of severe medical conditions requiring
intubation, severe sepsis, hypothermia, and anticipated length of insulin drop 2 weeks
and longer, pregnancy, Levemir allergy, and concurrent sulfonamide treatment
We found this trial at
1
site
University of Colorado Denver
13001 E. 17th Pl
Aurora, Colorado 80045
303-724-5000
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
?
mi
from
Aurora, CO
Click here to add this to my saved trials